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Background: Human cytomegalovirus (HCMV) infection is associated with cardiovascular disease (CVD) but the role
of this virus in CVD progression remains unclear. We aimed to examine the HCMV serostatus in Russian patients
(n = 90) who had undergone carotid endarterectomy (CEA) and controls (n = 82) as well as to determine the
prevalence of HCMV immediate early (IE) and late (LA) antigens in carotid atherosclerotic plaques obtained from 89
patients. In addition, we sought to determine whether HCMV infection was associated with inflammatory activity in
the plaque by quantifying infiltrating CD3 and CD68 positive cells and 5-LO immunoreactivity.
Methods: HCMV serology was assessed with ELISA and immunohistochemistry staining was performed to detect
HCMV antigens, CD3, CD68 and 5-LO reactivity. The Fisher’s exact test was used to compare i) seroprevalence of
HCMV IgG between patients and controls and ii) HCMV-positive or –negative to that of CD3, CD68 and 5-LO
immunoreactive cells in plaque samples. The student-t test was performed to connote the significance level of
mean optical density between patients and controls.
Results: The seroprevalence for HCMV IgG was high in both patients and controls (99% and 98%, respectively).
Controls had significantly higher IgG titers for HCMV compared with patients (p = 0.0148). Strikingly, we found a
high prevalence of HCMV antigens in atherosclerotic plaques; 57/89 (64%) and 47/87 (54%) were HCMV IE and LA
positive, respectively. Most plaques had rather low HCMV reactivity with distinct areas of HCMV-positive cells mainly
detected in shoulder regions of the plaques, but also in the area adjacent to the necrotic core and fibrous cap. In
plaques, the cellular targets for HCMV infection appeared to be mainly macrophages/foam cells and smooth muscle
cells. HCMV-positive plaques trended to be associated with increased numbers of CD68 positive macrophages and
CD3 positive T cells, while 5-LO reactivity was high in both HCMV-positive and HCMV-negative plaques.
Conclusions: In Russian patients undergoing CEA, HCMV proteins are abundantly expressed in carotid plaques and
may contribute to the inflammatory response in plaques via enhanced infiltration of CD68 and CD3 cells.
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Table 1 Patient demographics and characteristics
Clinical parameters Values
Male : Female (n) 72: 18
Age (mean ± SD) 62.0 ± 8.2
Symptoms, yes (%) 38.6 (32 of n*83)
Ipsilateral carotid stenosis (%) 78.0 ± 10.3 (of n*77)
Risk factors:
Smoking, yes (%) 48.1 (37 of n*77)
BMI (kg/m2) 26.7 ± 4.7 (of n*78)
Diabetes mellitus type 2, yes (%) 26.3 (21 of n*80)
Hypertension, yes (%) 96.3 (78 of n*81)
Total cholesterol (mmol/L) 5.6 ± 1.3 (of n*84)
Treatment:
Statins (%) 33.3% (27 of n*81)
Antiplatelet drugs (%) 82.5 (66 of n*80)
Antihypertensive drugs (%) 73.8 (59 of n*80)
BMI body mass index, values are mean ± SD if not indicated otherwise,
n* number of patients with available variant; Symptoms refer to transient
ischemic attack, ischemic stroke or retinal ischemia.
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Human cytomegalovirus (HCMV) is a DNA virus that
belongs to the family Herpesviridae [1]. It is a ubiquitous
but species-specific virus that remains latent in host cells
upon primary infection. Its seroprevalence varies from
40-100% depending on age, socioeconomic status and
geographical locations [2]. HCMV is known as an op-
portunistic infection in immunocompromised individ-
uals and it is the main etiological agent responsible for
congenital viral diseases [1]. Accumulating evidence also
supports a plausible role of microbial infection in the
pathogenesis of cardiovascular disease (CVD) [3]. For
example, many studies show the presence and probable
active role of microbes such as Chlamydia pneumonia,
Helicobacter pylori and certain periodontal pathogens or
viruses, such as herpes simplex virus and HCMV in the
pathogenesis of CVD [3,4]. Among these, HCMV and
Chlamydia pneumonia provide the strongest evidence of
a link to CVD through seroepidemiological, clinical and
experimental models [5-7].
HCMV has been proposed to influence various cardio-
vascular disease processes [3,8,9]. HCMV nucleic acids
and/or antigens have been detected in atherosclerotic
plaques [10,11]. Furthermore, elevated antibody levels
against HCMV are positively correlated with atheroscler-
osis [12], coronary artery disease [13] and more recently,
with CVD mortality [5,14-16]. In a mouse model, Cheng
et al. provided evidence that murine CMV possibly
results in enhanced arterial blood pressure through
increased angiotensin II [17]. Interestingly, patients with
essential hypertension have higher HCMV-specific micro-
RNA levels in plasma [18]. However, some studies have
also failed to detect the presence of HCMV in atheroscler-
otic plaques or show any association between this virus
and CVD [19,20]. Hence, the role of HCMV in CVD re-
mains controversial.
Inflammation is a well-established atherogenesis pro-
moter that increases CVD risk and contributes to plaque
rupture [21,22]. Among known proinflammatory media-
tors in CVD, leukotrienes are potent chemotactic mole-
cules, which attract leukocytes and induce vascular
permeability and smooth muscle cell contraction. 5-
lipoxygenase (5-LO) catalyzes the first steps in the con-
version of arachidonic acid to leukotrienes, and is im-
plied in the pathogenesis of atherosclerosis, restenosis
and plaque instability [23]. In atherosclerotic plaques,
the expression of 5-LO is mainly restricted to granulo-
cytes, monocytes/macrophages, foam cells, dendritic
cells, B cells and mast cells but not T cells [24]. HCMV
induces expression of both 5-LO mRNA and proteins as
well as leukotriene B4 (LTB4) production in infected
vascular smooth muscle cells [25], which otherwise are
unable to produce LTB4. HCMV could thereby contrib-
ute to local inflammation in the vascular wall and driveCVD progression. Inflammation is also a driving force for
reactivation of latent HCMV [26,27], and replication of this
virus in macrophages [28]. We therefore hypothesize that
HCMV positivity is associated with inflammation. In this
study, we aimed to determine the HCMV serostatus in
Russian patients who underwent carotid endarterectomy
(CEA) and in controls. We also sought to examine the
presence of HCMV immediate early (IE) and late (LA) an-
tigens in carotid atherosclerotic plaques and to search for
an association between HCMV positivity and enhanced
presence of inflammatory markers, i.e.: 5-LO, CD3 and
CD68 in CEA biopsy specimens.
Materials and methods
Specimens
Both sera (n = 90) and human atherosclerotic plaque tis-
sue samples (n = 89) were obtained from Russian patients
with CEA that were stored in St. Petersburg Investigation
of Carotid Endarterectomies (SPICE) Biobank (Table 1).
The Ethical Committee of Palvov State Medical University
of St. Petersburg approved the studies. Pieces of plaques
were embedded in Optimal Cutting Temperature com-
pound (Sakura Finetek, the Netherlands) and frozen for
immunohistochemistry or nucleic acid analysis. The con-
trol sera were from 83 control individuals and the study
was approved by the Institutional Review Board on cardi-
ology and endocrinology from the Almazov Federal Heart,
Blood and Endocrinology Centre, St. Petersburg. Among
these controls, 67 of them had ≤ 1.2 mm carotid intima-
media thickness and 16 of them had low degree of athero-
sclerosis whom at present had no symptoms.
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HCMV IgM titers were determined by ELISA (Enzygnost
anti-CMV/IgM, Siemens, Germany) and IgG by an in-
house anti-CMV/IgG ELISA assay, Karolinska University
Hospital, Sweden). This assay is used for routine clinical
diagnostics at the accredited Clinical Virology Laboratory
at the Karolinska University Hospital. We obtained com-
parable results by using this method and two commercial
kits (Afsar Rahbar, personal communication). The anti-
CMV/IgM ELISA was assayed in duplicates according to
the manual’s instruction. For the anti-CMV/IgG ELISA, an
in-house prepared 96-well plate coated with CMV/control
antigens was washed 3 times with washing buffer (0.9%
NaCl/0.05% Tween 20), incubated at 37°C, 60 mins with
plasma (1:500), thereafter washed 4 times and incubated
with polyclonal rabbit anti-human IgG conjugated to horse-
radish peroxidase (Dako, Denmark), 1:5000 in 1% BSA/PBS
for 5 mins on a shaker at RT and thereafter for 60 mins
at 37°C. After 4 washings, reactivity was detected using
o-phenylenediamine. The reaction was stopped with 2.5 M
sulphuric acid (Merck, Germany). The O.D. was read at
492 nm. The cut-off value for positivity was an O.D. > 0.2.
Immunohistochemistry (IHC)
IHC was performed with 8–10 μm thick acetone/metha-
nol-fixed cryosections using ImmPRESS detection sys-
tem. After endogenous peroxidase quenching, sections
were sequentially incubated with protein block, Fc re-
ceptor blocker, followed by normal horse serum, all for
20 mins at RT. Primary antibodies, mouse anti-HCMV
immediate early (IE, Millipore, MAB810R, clone 8B1.2,
1:500), mouse anti-HCMV late proteins (Millipore,
MAB8127, clone 1G5.2, 1:500), mouse anti-human
CD68 (Dako, M0876, clone PG-M1,1:200), mouse anti-
human CD3 (Dako, M7254, clone F7.2.38, 1:100) and
rabbit anti-5-LO (Abcam, ab39347, 1:400) were applied
and incubated overnight at 4°C. Negative controls were
prepared by omitting the primary antibody (TBS only)
or with isotype controls. HCMV VR1814-infected endo-
thelial cells served as positive controls. Immunoreactivity
was detected with diaminobenzidine (DAB) and counter-
stained with hematoxylin before microscope viewing.
The staining was graded according to the estimated per-
centage of positive cells with grade I denoting <25%;
grade II, 25-50%; grade III, 51-75% and grade IV, >75%
as previously described [29].
TaqMan PCR
Tissue plaques samples were cut into small pieces, incu-
bated with Proteinase K overnight and DNA was ex-
tracted using DNeasy Blood & Tissue kit (Qiagen). The
primers and probe sequences used for the HCMV IE
DNA detection were as previously described [30]. The
TaqMan reaction was performed with fast master mixusing ABI Prism 7900HT with the default thermocycling
profile using 50 ng as template in triplicates along with
positive and non-template controls. We used HCMV-
infected fibroblast cells as a positive control and a non-
template control of water as a negative control. In
addition, we also utilized the first WHO International
Standard for HCMV developed by NIBSC (code 09/162) to
make a standard curve in order to calculate the viral copy
number. In brief, the assigned 5 × 106 IU of HCMV in 1 ml
of nuclease-free water was subjected to DNA extraction
using QIAamp MinElute Virus Spin Kits (Qiagen) and the
DNA was eluted with 100 μl of nuclease-free water. A
standard curve was then generated using a serial of ten-
fold dilution with two microliter of each dilution was used
in a total volume of 10 μl reaction.
Statistical analysis
All statistical analysis was performed using GraphPad
Prism 5 software. The Fisher’s exact test was used to
compare i) seroprevalence of HCMV IgG between pa-
tients and controls and ii) HCMV-positive or –negative
to that of CD3, CD68 and 5-LO immunoreactive cells in
plaque samples. The student-t test was performed to
connote the significance level of mean optical density
between patients and controls. A p value < 0.05 was con-
sidered statistically significant.
Results
HCMV IgG titers are lower among CEA patients than
controls
Table 1 shows all the available patient demographics and
characteristics for 90 sera from CEA patients that were ex-
amined in our study. The ratio of males to females was 4:1
(i.e. males, n = 72 and females, n = 18) and the mean age
was 62.0 ± 8.2 (mean ± SD) for males and 65.8 ± 8.6 for
females. 89 of 90 (99%) sera from CEA patients were posi-
tive for HCMV IgG. One (1%) was positive for IgM and
three (3%) were equivocal (Figure 1A). From controls, we
obtained 83 serum samples; HCMV IgG and IgM titres
were determined in 82 samples by ELISA (1 sample was
insufficient in quantity for the assay). Females constituted
the major gender (n = 56) among controls (ratio male to
female approximately 1:2) with mean age of 56.8 ± 9.5 for
females compared to 52.2 ± 14.5 for males. The controls
showed similar patterns of HCMV IgG seroprevalence;
80/82 (98%) were HCMV IgG positive (Figure 1B), none
was IgM positive and 2/74 (3%) were equivocal for IgM
(Figure 1B). Thus, there was no significant difference in
HCMV IgG positivity between patients with CEA and
controls (p = 0.6059). However, we observed that controls
had a significantly higher O.D. value for HCMV IgG com-
pared to patients (1.95 ± 0.57 and 1.71 ± 0.68, respectively;
p = 0.0148, Figure 1C). Removal of 16 controls with low
degree of atherosclerosis resulted in the same conclusion
AB
C *p = 0.0148
Patients with carotid 
endarterectomy
Controls
Figure 1 Serological analysis of human cytomegalovirus (HCMV) antibodies in Russian patients with carotid endarterectomy (CEA) and
controls. (A) and (B) Bar graphs show seroprevalence of IgG and IgM antibodies against HCMV in patient with CEA or controls, respectively. (C)
Scatter plot shows optical density of IgG between patients with CEA and controls. Carotid endarterectomy, CEA; Optical density, O.D.; *p < 0.05.
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Figure 2 Immunoreactivity and grading of human cytomegalovirus (HCMV) antigens and inflammatory markers in human carotid
atherosclerotic plaques as assayed by immunohistochemistry (IHC) staining. (A) Summary of IHC results on viral immediate early (IE), late
(LA), 5-LO, CD3 and CD68 in plaques. (B-E) Panel of controls consist of omitting primary antibody (or Tris-buffered saline, TBS only) instead of IE
(B), isotype control for LA (C), isotype control for IE (D), and virus-infected endothelial cells (E). (F-G) Immunoreactivity and grading of IE (F) or
LA (G) in plaques. (H) Association between HCMV IgG antibodies and its IE antigens burden. Positivity was revealed by diaminobenzidine (DAB),
brown products; Optical density, O.D.
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tient with CEA and controls.
HCMV IE and LA are frequently present in atherosclerotic
plaques
We examined 89 frozen tissue samples obtained from CEA
patients for HCMV IE and 87 for HCMV LA. Strikingly,
57/89 (64%) and 47/87 (54%) were positive for HCMV IE
and LA, respectively (Figure 2A). Minimal or no HCMV
immunoreactivity was detected in sections incubated with
TBS (i.e. omitting primary antibody) (Figure 2B) or using
isotype control antibodies (IgG1 and IgG2a) (Figure 2C-2D,
respectively). Endothelial cells infected in vitro were positive
for HCMV IE and LA (Figure 2E).
To confirm the presence of HCMV nucleic acids in
plaques, we randomly selected 9 samples from HCMV
IHC-positive and 9 samples of IHC-negative tissue pla-
ques, isolated DNA and performed TaqMan PCR ana-
lysis for HCMV. We detected 4/9 (44%) samples positive
for IE DNA, while none of nine IHC-negative plaques
was positive for HCMV IE (Table 2). We used HCMV-Table 2 TaqMan PCR analysis and cellular localization of viral
antigens
Sample Viral antigens localization as revealed by
CP 03 Endothelial cells, macrophage/foam cell
CP 05 Endothelial cells, macrophage/foam cell
CP 30 Endothelial cells +/−, macrophage/foam c
CP 31 Smooth muscle ce
CP 36 Macrophage/foam cells, inflammatory cells
CP 37 Endothelial cells, macrophage/foam cell
CP 44 Endothelial cells, macrophage/foam cells, inflamm
CP 47 Macrophage/foam cells, smooth
CP 101 Macrophage/foam cells, smooth
CP 08 None detected
CP 24 None detected
CP 27 None detected
CP 49 None detected
CP 51 None detected
CP 102 None detected
CP 109 None detected
CP 122 None detected
CP 123 None detectedinfected fibroblast cells as positive control for the PCR
assay, which was always positive, with an average thresh-
old cycle = 15.0 ± 0.2 (equivalent to 7.7 × 109 IU/ml). The
non-template control consisting of water was consist-
ently negative. The sensitivity limit of our assay was de-
termined to be 765 IU/ml using the WHO International
Standard for HCMV. We failed to extract RNA from 10
samples (each 10 tissues section slices) that was suffi-
cient in both quantity and quality to perform TaqMan
PCR as assessed by NanoDrop 2000 (Thermo Scientific).
To quantify HCMV immunoreactivity in CEA samples,
we graded positive staining (Figure 2F-2G) as previously
described [29]. HCMV immunoreactivity was either grade
I or grade II. Grade I was the most prevalent for IE (43/57
or 75%) and all LA positive samples were grade I
(Figure 3D). Cells expressing HCMV antigens were
mainly detected in the shoulder regions of the plaques,
in areas adjacent to the necrotic core and occasionally
also in the fibrous cap (Figure 2F, 2+). The cellular tar-
gets for HCMV infection was mainly macrophages/
foam cells and smooth muscle cells although we alsoantigens on selected IHC-positive or -negative for HCMV
immunohistochemistry TaqMan PCR (IU/ml)
s, smooth muscle cells 10,298
s, smooth muscle cells 2,598
ells, smooth muscle cells Undetermined
lls Undetermined
, smooth muscle cells +/− Undetermined
s, smooth muscle cells 7,956
atory cells, smooth muscle cells Undetermined
































Figure 3 Immunoreactivity and grading of inflammatory markers in association to human cytomegalovirus (HCMV) antigens burden.
(A-C) Immunoreactivity and grading of 5-lipoxygenase (5-LO) (A), CD3 (B) and CD68 (C) in plaques. (D) Summary of grading results for HCMV
immediate early (IE), late antigen (LA), 5-LO, CD3 and CD68 in plaques. (E-G) Association of HCMV IE antigens with 5-LO (E), CD3 (F) and CD68
(G). Positivity was revealed by diaminobenzidine (DAB), brown products.
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other infiltrating inflammatory cells (Figure 2B-2D and
Figure 2F-2G).
To address the question whether any association exists
between HCMV IgG titers and viral burden in carotid
plaques, we combined the results obtained from the
serology and viral IE antigens staining analyses. Among
51 patients who were positive for HCMV IE, 10 (20%)
patients had O.D. < 1 and 41 (80%) patients had O.D. >
1. Among 30 HCMV IE negative patients, 6 (20%) had
O.D. < 1 and 25 (80%) had O.D. > 1 (Figure 2H). Thus,
we did not observe any association between viral antigen
burden in the plaque and HCMV IgG levels.
HCMV trended to be associated with increased
inflammatory burden
We next assessed if there was an association between
HCMV infection and inflammatory markers. We stained
tissue samples from CEA patients for 5-LO, CD3 and
CD68; -all representing markers of inflammation. We
found that 78/81 (96%), 79/82 (96%) and 84/84 (100%) ofthe CEA plaques were positive for 5-LO, CD3 and CD68,
respectively (Figure 2A). We also graded these samples
according to positivity (grade I-IV) as exemplified in
Figure 3A-3C and summarized in Figure 3D. 5-LO pro-
teins were abundantly expressed in macrophage/foam
cells and in smooth muscle cells; 38 of 81 (47%) samples
were grade III or IV (Figure 3D). All examined plaques
were positive for CD68 (Figure 3D); 51 of 84 (61%) samples
were grade III or IV (Figure 3D). CD3-positive cells were
less abundant; 51 of 82 (62%) samples were grade I, none
was grade II-IV. Thus, CD68-positive macrophages and
5-LO immunoreactivity were highly abundant in athero-
sclerotic plaques, relative to CD3-positive T cells that were
less frequently observed in CEA plaques (Figure 3D).
Next, we divided samples by the grade of HCMV IE ex-
pression and compared staining results from 5-LO, CD3
and CD68 to determine whether IE positivity was associ-
ated with a higher grade (grade II and above) of the in-
flammatory markers. We found no statistically significant
difference in the grade of inflammatory markers between
those that were low HCMV IE vs. high HCMV IE
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0.3408) and IE vs. CD3 (p = 0.0920). However, we ob-
served a trend for higher immunoreactivity among
HCMV-positive plaques for CD3 and CD68 compared to
that of HCMV-negative plaques (Figure 3E-3G), indicating
that HCMV may be involved in driving the inflammatory
process or may be associated with this process.Discussion
We found a high prevalence of HCMV protein expression
in atherosclerotic plaques, suggesting an ongoing active
HCMV replication in a majority of atherosclerotic pla-
ques. As viral antigens by their nature as foreign antigens
provide targets for the immune system, it is plausible that
some immune reactivity existing in the plaque is directed
against HCMV peptides. This statement is supported by
the fact that we found a trend for increased number mac-
rophages and T cells in HCMV-positive plaques.
The life cycle of HCMV intrinsically involves macro-
phages and inflammation. HCMV maintains latency in
myeloid lineage cells and becomes reactivated in macro-
phages differentiated by inflammatory stimuli [31]. HCMV
can induce inflammation by inducing 5-LO and COX-2 ex-
pression with consequent leukotriene and prostaglandin E2
production [25,32]. Furthermore, HCMV also increases the
production of pro-inflammatory cytokines, e.g. IL-1β, IL-4,
IL-6, IL-8, TNF-α and IFN-γ [33]. The HCMV US28 and
IE proteins induce production of IL-6 [32,34], which pro-
vides a direct link to C-reactive protein (CRP) levels. Both
IL-6 and CRP are widely used markers for systemic inflam-
mation and predictors of coronary heart disease [35].
We detected HCMV IE DNA in 44% (n = 9) of the
HCMV antigen positive plaques while no HCMV IE DNA
existed in HCMV antigen negative plaques (n = 9). In 75
arterial vascular tissues, a similar detection rate of HCMV
DNA was reported [36]. As we found HCMV present
mainly in the shoulder region and we had access to DNA
from undefined parts of the plaques, it is possible that
viral DNA was absent in some of the samples analyzed.
Our PCR assay has a sensitivity of 765 IU/ml, which is
also a limiting factor. Furthermore, it is possible that some
clinical HCMV strains are not detected by our assay,
which is supported by our own unpublished data from
cancer patients who demonstrate variability in the IE and
gB genes sometimes resulting in lack of detection of viral
genes by both our PCR assays. We also failed to retrieve
RNA in sufficient quantity and quality from 10 samples to
proceed with cDNA synthesis or PCR analysis. It is pos-
sible that failure to retrieve RNA was due to low amount
of RNA in the necrotic core of the end-stage plaques and
we were unable to determine exactly from where in the
specimen the section came from. Also it is well-known
that RNA is sensitive to degradation depending on storageconditions, which may also explain why we did not re-
cover enough RNA for further analyses.
To our knowledge, only two earlier reports examined
the presence of HCMV protein expression in athero-
sclerotic plaques with reasonably large sample cohorts
[37,38]. Chiu et al. reported that 27/76 atherosclerotic
plaques obtained from Canadians (35.5%) were immuno-
reactive for HCMV early antigens [37], and Yi et al. de-
tected a similar HCMV IE positivity (12/35 or 34.2%)
and less expression of HCMV LA antigens (4/35 or
11.4%) in samples from Chinese Han patients [38]. We
detected HCMV IE antigens in 57/89 (64%), and LA an-
tigens in 47/87 (54%) of atherosclerotic plaques obtained
from Russian patients. The higher percentage of immu-
noreactivity against viral antigens observed in this cohort
may be due to different sample handling; both Chiu
et al. and Yi et al. examined formalin-fixed samples,
while we used frozen samples. Detection of HCMV pro-
teins in cancer specimens is facilitated by antigen re-
trieval protocols, which results in enhanced sensitivity of
the assay to similar detection levels as is observed in fro-
zen tissue sections [39]. The HCMV serostatus of 99%
(89/90) was also higher in our cohort than reported by
Chiu et al. (50/76 or 65.8%) while not examined by Yi
et al. Thus, ethnic differences may exist [40] regarding
the prevalence of HCMV in CEA patients.
Elevated antibody levels against HCMV was shown by
others to correlate positively with atherosclerosis [12], cor-
onary artery disease [13] and CVD mortality [5,14-16]; but
a lack of correlation between HCMV antibodies in patients
with CEA compared with controls, were also reported
[37,41]. In the present study, we did not observe a signifi-
cant difference between the prevalence of HCMV IgG
antibodies in patients with CEA compared to controls;
both groups had similar IgG prevalence. However, we did
observe lower viral O.D. values in patients than controls.
It is possible that the adaptive immune response to
HCMV is less efficient in individuals who are at higher
risk of developing atherosclerosis, or that the virus by itself
provides immunosuppressive mechanisms. It is also well
known that HCMV has developed multitude of sophisti-
cated mechanisms to avoid detection by the immune
system [31,42,43], which may also explain the high preva-
lence of HCMV antigen reactivity in CEA patients, who
had lower OD values than controls.
The concept of a low grade infection is in line with
emerging views that there is an association between
chronic low grade inflammation or infection and the
slow process of arteriosclerosis [44]. HCMV induces ex-
pression of both 5-LO mRNA and proteins in addition
to LTB4 production in infected smooth muscle cells
[25]. Here, we detected 5-LO expression in HCMV-
infected smooth muscle cells besides macrophage/foams
cells, which substantiate our previous findings that 5-LO
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otherwise do not express 5-LO. We observed that the pro-
portion of 5-LO positive plaques were higher in plaques
with higher HCMV antigen burden, but was not higher in
HCMV positive versus negative plaques. Thus, other mech-
anisms than HCMV can also induce 5-LO mediated inflam-
mation in vascular cells. High number of CD68-positive cells
were associated with 5-LO expression levels (Figure 3B-3C),
indicating that the main source of 5-LO was from macro-
phages, as was previously proposed [45]. Carotid atheroscler-
otic plaques containing enhanced numbers of CD3- and
CD68-positive cells as indicators of increased inflammatory
activity trended to be more often HCMV positive.
In summary, HCMV IE and LA antigens are abun-
dantly expressed in carotid atherosclerotic plaques ob-
tained from Russian patients. The seroprevalence of
HCMV was very high in both Russian patients with
CEA as well as in controls, but the IgG titers were sig-
nificantly lower among patients than controls. There
was abundant 5-LO expression and a substantial infiltra-
tion of CD68-positive macrophages in plaques, but rela-
tively less prevalent infiltration of CD3-positive T cells.
We observed a trend for increased infiltration of CD3-
positive T cells and macrophages in HCMV-positive pla-
ques, suggesting that this virus may influence the inflam-
matory activity in atherosclerotic plaques.
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